Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 5/20 | 0.37 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.33 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.33 |
| ▸ | KIF11 | P52732 | 1/20 | 0.31 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.30 |
| ▸ | WNT3A | P56704 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14165902 | 1.00 | KCNN4 (0.37) | KCNN4KCNE1KCNQ1KIF11CTNNB1 | |
| SCHEMBL12273629 | 0.85 | KCNN4 (0.36) | KCNN4KCNE1KCNQ1KIF11 | |
| SCHEMBL14690376 | 0.77 | KCNN4 (0.38) | KCNN4KCNE1KCNQ1KIF11CTNNB1 | |
| SCHEMBL15536032 | 0.72 | KCNN4 (0.42) | KCNN4KCNE1KCNQ1KIF11CTNNB1 | |
| SCHEMBL15602054 | 0.72 | KCNN4 (0.42) | KCNN4KCNE1KCNQ1KIF11CTNNB1 | |
| SCHEMBL21677155 | 0.71 | KCNN4 (0.39) | KCNN4KCNE1KCNQ1KIF11CTNNB1 | |
| SCHEMBL18683297 | 0.71 | KCNN4 (0.39) | KCNN4KCNE1KCNQ1KIF11CTNNB1 | |
| SCHEMBL30148544 | 0.71 | KCNN4 (0.40) | KCNN4KCNE1KCNQ1KIF11CTNNB1 | |
| SCHEMBL9277677 | 0.71 | KCNN4 (0.40) | KCNN4KCNE1KCNQ1KIF11CTNNB1 | |
| Hydrochloric Acid SCHEMBL16833856 | 0.71 | KCNN4 (0.41) | KCNN4KCNE1KCNQ1KIF11CTNNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8987255-B2 | Halogen-alkyl-1,3 oxazines as BACE1 and/or BACE2 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-20140080819-A1 | HALOGEN-ALKYL-1,3 OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2014-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140080819-A1 | HALOGEN-ALKYL-1,3 OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS | BACE2, BACE1, APP | KCNN4 4149/4885KCNE1 1738/4885KCNQ1 1209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.